Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum93050ArticlesСтатьиResearch ArticleMesto bronkhodilatatora dlitel'nogo deystviya tiotropiya bromida v modifikatsii zabolevaniya pri khronicheskoy obstruktivnoy bolezni legkikhМесто бронходилататора длительного действия тиотропия бромида в модификации заболевания при хронической обструктивной болезни легкихVizel'A. AВизельА. АVizel'I. YuВизельИ. ЮГОУ ВПО «Казанский государственный медицинский университет Росздрава»151120091111VOL 11, NO11 (2009)ТОМ 11, №11 (2009)616828122021Copyright ©; 2009, Consilium MedicumCopyright ©; 2009, ООО "Консилиум Медикум"2009Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/93050

Хроническая обструктивная болезнь легких (ХОБЛ) – хроническое экологически опосредованное воспалительное заболевание респираторной системы с поражением воздухоносных путей и легочной паренхимы с развитием эмфиземы, проявляющееся частично обратимой бронхиальной обструкцией, характеризующееся прогрессированием и нарастающими явлениями хронической дыхательной недостаточности. В 2004 г. оно было признано экспертами Старого и Нового Света предотвратимым и курабельным заболеванием [1]. Возможность замедлить, стабилизировать, а иногда и улучшить функцию внешнего дыхания (ФВД) больных с ХОБЛ связывают с появлением в клинической практике тиотропия бромида (ТБ) [2], комбинаций сальметерол/флутиказон, формотерол/будесонид [3], применением трех типов препаратов одновременно [4], а также с созданием новых противовоспалительных средств, таких как ингибиторы фермента фосфодиэстеразы-4 или средств, способных влиять на регенерацию тканей [5]. Наиболее обнадеживающие результаты в настоящее время дают исследования ТБ.

Celli B.R., Mac Nee W and committee members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper//Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932–46.Лещенко И.В. Глобальная инициатива при хронической обструктивной болезни легких 2006: значение длительно действующих бронходилататоров. Consilium Medicum 2007; 9 (10): 10–3.Nannini L, Cates C.J., Lasserson T.J., Poole P. Combined corticosteroid and long acting beta - agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2004; 3: CD003794.Aaron S.D., Vandemheen K, Fergusson D et al. The Canadian Optimal Therapy of COPD Trial: Design, organization and patient recruitment. Can Respir J 2004; 11 (8): 581–5.Miravitlles M. New treatments for chronic obstructive pulmonary disease. Med Clin (Barc) 2005; 125 (2): 65–74.Авдеев С.Н. Возможна ли модификация заболеваний при хронической обструктивной болезни легких? Роль бронходилататора длительного действия тиотропия бромида. Consilium Medicum 2008; 10 (3): 57–64.Овчаренко С.И., Голиковой Е.П. Спирива – эффективный препарат, уменьшающий одышку и частоту обострений при хронической обструктивной болезни легких (данные клинических испытаний). Пульмонология. 2003; 6: 103–7.Anzueto A. Clinical course of chronic obstructive pulmonary disease: review of therapeutic interventions. Am J Med 2006; 119 (10 Suppl. 1): 46–53.O\'Connor B.J., Towse L., Barnes P.J. Prolonged effect of tiotropium bromide on methacholine - induced bronchoconstriction in asthma. Am J Respir Crit Care Med 1996; 154 (4, Pt 1): 876–80.Littner M.R., Ilowite J.S., Tashkin D.P. et al. Long - acting bronchodilation with once - daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161 (4, Pt 1): 1136–42.Casaburi R, Briggs D.D.Jr, Donohue J.F. et al. The spirometric efficacy of once - daily dosing with tiotropium in stable COPD: a 13 - week multicenter trial. The US Tiotropium Study Group. Chest 2000; 118 (5): 1294–302.van Noord J.A., Bantje T.A., Eland M.E. et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000; 55 (4): 289–94.Barnes P.J. Tiotropium bromide. Expert Opin Investig Drugs 2001; 10 (4): 733–40.Casaburi R, Mahler D.A., Jones P.W. et al. A long - term evaluation of once - daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19 (2): 217–24.Celli B, Zu Wallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124 (5): 1743–8.Mc Nicholas W.T., Calverley P.M., Lee A, Edwards J.C. Tiotropium Sleep Study in COPD Investigators: Long - acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD. Eur Respir J 2004; 23 (6): 825–31.Визель А.А., Пронина Е.Ю., Сергеев В.А. и др. Тиотропия бромид в комплексной терапии больных с ХОБЛ: оценка эффекта первой упаковки. Клин. фармакол. и тер. 2005; 4: Прил. Тезисы I конференции «Качественное использование лекарств и фармаконадзор», Казань: 162–3.Niewoehner D.E., Rice K, Cote C et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once - daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005; 143 (5): 317–26.Friedman M, Menjoge S.S., Anton S.F., Kesten S. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with Chronic Obstructive Pulmonary Disorder (COPD). Pharmacoeconomics 2004; 22 (11): 741–9.Laforest L, Ritleng C, Van Ganse E. Dispensing patterns of tiotropium at initiation in patients from the rhone - alpes region: results from an observational survey. Eur Resp J 2009; 34 (Suppl. 53): Ref. E1451.Somand H, Remington T.L. Tiotropium: A bronchodilator for Chronic Obstructive Pulmonary Disease. Ann Pharmacother 2005; 39 (9): 1467–75.Barr R.G., Bourbeau J, Camargo C.A., Ram F.S. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; 2: CD002876.Dusser D, Bravo M.L., Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2006; 27 (3): 547–55.Anzueto A. Clinical course of chronic obstructive pulmonary disease: review of therapeutic interventions. Am J Med 2006; 119 (10 Suppl. 1): 46–53.van Noord J.A., Cornelissen P.J., Aumann J.L. et al. The efficacy of tiotropium administered via Respimat(R) Soft Misttrade mark Inhaler or HandiHaler(R) in COPD patients. Respir Med 2009; 103 (1): 22–9.Decramer M, Celli B, Kesten S, Lystig T et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomized controlled trial. Lancet 2009 Aug 27. Epub ahead of print.Celli B, Decramer M, Kesten S et al. Mortality in the 4 Year Trial of Tiotropium (UPLIFT) in Patients with COPD. Am J Respir Crit Care Med 2009; Sep 3. Epub ahead of print.Tashkin D.P., Celli B, Kesten S et al. Long - term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur Respir J 2009; Aug 28. Epub ahead of print.Celli B, Kesten S, Lystig T et al.COPD patients under 50 years of age: 4-year follow - up in the UPLIFT trial. Europ Resp J 2009; 34 (Suppl. 53): Ref. P3801.Troosters T, Celli D, Kesten S et al. Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the uplift trial. Eur Resp J 2009; 34 (Suppl. 53): Ref. P3808.Hanania N, Kesten S, Celli B et al. Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium. Eur Resp J 2009; 34 (Suppl. 53): Ref. E4353.Tashkin D, Kesten S. Long - term treatment benefits with tiotropium in COPD patients with and without short - term bronchodilator responses. Chest 2003; 123 (5): 1441–9.Myronenko O. Respiratory muscles\' function in chronic obstructive pulmonary disease patients treted with anticholinergic bronchodilator. Eur Resp J 2009; 34 (Suppl. 53): Ref. P3508.Yoshimura K, Hiraga T, Kitada S et al. Effects of tiotropium on neurohumoral activation during exercise in stable COPD patients. Eur Resp J 2009; 34 (Suppl. 53): Ref. E4364.Hasani A, Toms N, Agnew J.E. et al. The effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPD. Chest 2004; 125 (5): 1726–34.Pertseva T, Lykholat O, Gurzhiy O. Influence of tiotropium bromide (TB) on mucociliary clearance (MCC) in patients with COPD. Eur Resp J 2009; 34 (Suppl. 53): Ref. P3458.Dicpinigaitis P.V., Spinner L, Santhyadka G, Negassa A. Effect of Tiotropium on cough reflex sensitivity in acute viral cough lung. 2008; 186 (6): 369–74.Saito Y, Azuma A, Morimoto T et al. Tiotropium ameliorates symptoms in patients with chronic airway mucus hypersecretion which is resistant to macrolide therapy. Intern Med 2008; 47 (7): 585–91.Bu.hling F, Lieder N, Ku.hlmann U.C. et al. Tiotropium suppresses acetylcholine - induced release of chemotactic mediators in vitro. Respir Med 2007; 101 (11): 2386–94.Pieper M.P., Chaudhary N.I., Park J.E. Acetylcholine - induced proliferation of fibroblasts and myofibroblasts in vitro is inhibited by tiotropium bromide. Life Sci 2007; 80 (24–25): 2270–3.Shikama Y, Asano K, Shibuya Y et al. Suppressive activity of tiotropium bromide on matrix metalloproteinase production from lung fibroblasts in vitro. Eur Resp J 2009; 34 (Suppl. 53): Ref. P4668.Wollin L, Pieper M. Tiotropium bromide exerts anti - inflammatory activity in a cigarette smoke mouse model of COPD. Eur Resp J 2009; 34 (Suppl. 53): Ref. P2004.Ishii Y, Fujimoto S, Baba C, Fukuda T. Tiotropium inhalation prevents acute cigarette smoke - induced airway inflammation in mice. Eur Resp J 2009; 34 (Suppl. 53): Ref. P937.Zaagsma J, Pera T, Zuidhof A.B. et al. Remoddeling and inflammation in a guinea pig model of COPD: effects of tiotropium. Eur Resp J 2009; 34 (Suppl. 53): Ref. E2944.Shibuya Y, Shikama Y, Asano K et al. Attenuating effect of tiotropium bromide on IL - 8 production from human bronchial epithelial cells, BEAS-2B in vitro. Eur Resp J 2009; 34 (Suppl. 53): Ref. P863].Profita M, Riccobono L, Montalbano A.M. et al. Non - neuronal components of cholinergic system in peripheral blood T - cells of COPD patients. Eur Resp J 2009; 34 (Suppl. 53): Ref. P915.Zu Wallack A.R., Zu Wallack R.L. Tiotropium bromide, a new, once - daily inhaled anticholinergic bronchodilator for chronic - obstructive pulmonary disease. Exp Opin Pharmacother 2004; 5 (8): 1827–35.Matera M.G., Sanduzzi A, Ponticiello A et al. An acute bronchodilator test with tiotropium or salmeterol does not allow a subdivision of patients according to responses. Respiration 2005; 72 (5): 466–70.Salvi S, Bhosle K, Brashier B et al. Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate - to - severe asthma. Eur Resp J 2009; 34 (Suppl. 53): Ref. E276.Baloira Villar A, Vilarino Pombo C. Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease. Arch Bronconeumol 2005; 41 (3): 130–4.Bateman E.D., van Dyk M, Sagriotis A. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: A pilot study. Pulm Pharmacol Ther 2008; 21 (1): 20–5.Aaron S.D., Vandemheen K, Fergusson D et al. The Canadian Optimal Therapy of COPD Trial: Design, organization and patient recruitment. Can Respir J 2004; 11 (8): 581–5.Wedzicha J.A., Calverley P.M., Seemungal T.A. et al. INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177 (1): 19–26.Aaron S.D., Vandemheen K.L., Fergusson D et al. Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone - salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146 (8): 545–55.Biscione G, Crigna G, Auciello L et al. Addition of tiotropium (T) to a regular treatment with long - acting beta - agonist+inhaled corticosteroid (LABA+ICS) in patients with severe to very - severe COPD under in - patient pulmonary rehabilitation program (PRP). Eur Resp J 2009; 34 (Suppl. 53): Ref. P526.Cazzola M, Marco F.D., Santus P et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 2004; 17 (1): 35–9.van Noord J.A., Aumann J.L., Janssens E et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26 (2): 214–22.Terzano C, Petroianni A. Rational timing of combination therapy with tiotropium and formoterol in moderate - severe COPD. Eur Resp J 2006; 28 (Suppl. 50): Ref. P1272.Vogelmeier C, Kardos P, Harari S et al. Formoterol monoand combination therapy with tiotropium in patients with COPD: A 6 - month study. Respir Med 2008; 102 (11): 1511–20.Rabe K.F., Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD Chest 134 (2): 255–62.Welte T, Miravitlles M, Hernandez P et al. Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms & morning activities in COPD patients. Eur Resp J 2009; 34 (Suppl. 53): Ref. P2005.Welte T, Miravitlles M, Hernandez P et al. Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation - related antibiotic use in patients with COPD. Europ Resp J 2009; 34 (Suppl. 53): Ref. P2012.